Medtronic strikes loan agreement with Saluda Medical for spinal cord simulation study: 3 details

Written by Alan Condon | June 27, 2019 | Print  |

Saluda Medical agreed a four-year loan with Medtronic to develop its Evoke evoked action compound potential-controlled, Closed-Loop Spinal Cord Stimulation System for the treatment of chronic intractable pain of the trunk and limbs.

Three insights:

1. The ECAP-controlled SCS system is Saluda's debut device, which measures the spinal cord's response to stimulation.

2. The device adjusts on every pulse to maximize activation within the patient's therapeutic window and seeks to maintain long-term results through ECAP control.

3. Medtronic is an existing shareholder of Saluda Medical after participating in two prior financing rounds. Further terms of the loan were not disclosed.

"This funding provides us with the financial flexibility to accelerate further development of our novel closed-loop SCS system and prepare for commercialization," said John Parker, CEO of Saluda Medical. "We are passionate about bringing ECAP-controlled, closed-loop technology to the field of pain management to develop mechanistic-based therapies for patients."

More articles on devices:
Dr. Zeeshan Sardar: 4 considerations when adapting a new spine device
Medeon Biodesign close financing of Panther Orthopedics fixation technology
Benvenue Medical minimally invasive spine device receives FDA clearance


© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months